← Leaderboards
Ramesh Narayanan
University Of Tennessee Health Sci Ctr
$3,467,012
Attributed
$3,467,012
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $811.8K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,467,012 · 2
By mechanism
R01$3,467,012 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Property”
- Valerie Koch · University Corporation For Atmospheric Res$247,762,266
- Susan Abushakra · Alzheon, Inc.$47,265,244
- John Hobbs · Suny At Stony Brook$42,194,917
- Christopher Bee · Suny At Stony Brook$41,239,084
- John Damon Chodera · Sloan-Kettering Inst Can Research$39,689,447
- Eric C Palm · Florida State University$35,115,872
Research focus
PropertyAndrogen ReceptorBindingRattusCastrationIn VitroStructure-Activity RelationshipLeadReceptor ActivationScreeningIn VivoResistanceClinical DevelopmentLiver MicrosomesDrug KineticsProteinsTransactivationPharmaceutical PreparationsMalignant Neoplasm Of ProstateImproved OutcomeBiological AvailabilityDoseModificationCastration Resistant Prostate Cancer
Grant awards (11)
Discovery of Novel Selective Androgen Receptor Degraders (SARDs) for the Treatment of Spinobulbar Muscular Atrophy (SBMA) or Kennedyâs Disease$337,272
R01 · FY2025 · NS · contact PI
Discovery of Novel Selective Androgen Receptor Degraders (SARDs) for the Treatment of Spinobulbar Muscular Atrophy (SBMA) or Kennedyâs Disease$380,249
R01 · FY2024 · NS · contact PI
Novel Degraders of the Androgen Receptor (AR) and AR Splice Variants (AR-SVs)$397,317
R01 · FY2023 · CA · contact PI
Novel Degraders of the Androgen Receptor (AR) and AR Splice Variants (AR-SVs)$398,462
R01 · FY2022 · CA · contact PI
Novel Degraders of the Androgen Receptor (AR) and AR Splice Variants (AR-SVs)$46,178
R01 · FY2022 · CA · contact PI
Novel Degraders of the Androgen Receptor (AR) and AR Splice Variants (AR-SVs)$684,995
R01 · FY2021 · CA · contact PI
Discovery and Development of Selective Androgen Receptor Irreversible Covalent Antagonist (SARICA)$126,825
R01 · FY2021 · CA · contact PI
Novel Degraders of the Androgen Receptor (AR) and AR Splice Variants (AR-SVs)$411,723
R01 · FY2020 · CA · contact PI
Racial Disparity in the Expression of Androgen Receptor Splice Variants (AR-SVs) in Prostate Cancer$228,000
R01 · FY2020 · CA · contact PI
Novel Degraders of Androgen Receptor (AR) and AR Splice Variants (AR-SVs)$47,120
R01 · FY2020 · CA · contact PI
Novel Degraders of the Androgen Receptor (AR) and AR Splice Variants (AR-SVs)$408,871
R01 · FY2019 · CA · contact PI